This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patron, R. L.
Right arrow Articles by Archer, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patron, R. L.
Right arrow Articles by Archer, G. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1754-1755, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin

Roberto L. Patron,1 Michael W. Climo,1,2,* Beth P. Goldstein,3 and Gordon L. Archer1,4

Department of Internal Medicine1 and Microbiology/Immunology,4 Medical College of Virginia Campus of Virginia Commonwealth University, and Hunter Holmes McGuire Veterans Affairs Medical Center,2 Richmond, Virginia, and AMBI, Inc., Purchase, New York3

Received 4 December 1998/Returned for modification 4 February 1999/Accepted 6 April 1999

The rabbit model of endocarditis was used to test the effectiveness of vancomycin and two different lysostaphin dosing regimens for the treatment of infections caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin (glycopeptide-intermediate susceptible S. aureus [GISA]). Vancomycin was ineffective, with no evidence of sterilization of aortic valve vegetations. However, rates of sterilization of aortic valve vegetations were significantly better for animals treated with either a single dose of lysostaphin (43%) or lysostaphin given twice daily for 3 days (83%) than for animals treated with vancomycin. Rabbits given a single dose of lysostaphin followed by a 3-day drug-free period had mean reductions in aortic valve vegetation bacterial counts of 7.27 and 6.63 log10 CFU/g compared with those for untreated control rabbits and the vancomycin-treated group, respectively. We conclude that lysostaphin is an effective alternative for the treatment of experimental aortic valve endocarditis caused by a clinical VISA strain.

* Corresponding author. Mailing address: McGuire Veterans Affairs Medical Center, 1201 Broad Rock Blvd., Section 111-C, Richmond, VA 23249. Phone: (804) 675-5018. Fax: (804) 675-5437. E-mail: Climo.Michael{at}Richmond.va.gov or MWCLIMO{at}aol.com.

Antimicrobial Agents and Chemotherapy, July 1999, p. 1754-1755, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Tan, Y. P., Giffard, P. M., Barry, D. G., Huston, W. M., Turner, M. S. (2008). Random Mutagenesis Identifies Novel Genes Involved in the Secretion of Antimicrobial, Cell Wall-Lytic Enzymes by Lactococcus lactis. Appl. Environ. Microbiol. 74: 7490-7496 [Abstract] [Full Text]  
  • Kokai-Kun, J. F., Chanturiya, T., Mond, J. J. (2007). Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 60: 1051-1059 [Abstract] [Full Text]  
  • Kusuma, C., Jadanova, A., Chanturiya, T., Kokai-Kun, J. F. (2007). Lysostaphin-Resistant Variants of Staphylococcus aureus Demonstrate Reduced Fitness In Vitro and In Vivo. Antimicrob. Agents Chemother. 51: 475-482 [Abstract] [Full Text]  
  • Wootton, M., MacGowan, A. P., Walsh, T. R., Howe, R. A. (2007). A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides. J. Clin. Microbiol. 45: 329-332 [Abstract] [Full Text]  
  • Yang, X.-Y., Li, C.-R., Lou, R.-H., Wang, Y.-M., Zhang, W.-X., Chen, H.-Z., Huang, Q.-S., Han, Y.-X., Jiang, J.-D., You, X.-F. (2007). In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol 56: 71-76 [Abstract] [Full Text]  
  • Qin, Z., Yang, X., Yang, L., Jiang, J., Ou, Y., Molin, S., Qu, D. (2007). Formation and properties of in vitro biofilms of ica-negative Staphylococcus epidermidis clinical isolates. J Med Microbiol 56: 83-93 [Abstract] [Full Text]  
  • Baker, J. R., Liu, C., Dong, S., Pritchard, D. G. (2006). Endopeptidase and glycosidase activities of the bacteriophage b30 lysin.. Appl. Environ. Microbiol. 72: 6825-6828 [Abstract] [Full Text]  
  • Grundling, A., Missiakas, D. M., Schneewind, O. (2006). Staphylococcus aureus Mutants with Increased Lysostaphin Resistance.. J. Bacteriol. 188: 6286-6297 [Abstract] [Full Text]  
  • Kusuma, C. M., Kokai-Kun, J. F. (2005). Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3256-3263 [Abstract] [Full Text]  
  • Fujiwara, T., Aoki, S., Komatsuzawa, H., Nishida, T., Ohara, M., Suginaka, H., Sugai, M. (2005). Mutation Analysis of the Histidine Residues in the Glycylglycine Endopeptidase ALE-1. J. Bacteriol. 187: 480-487 [Abstract] [Full Text]  
  • Pritchard, D. G., Dong, S., Baker, J. R., Engler, J. A. (2004). The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Microbiology 150: 2079-2087 [Abstract] [Full Text]  
  • Barequet, I. S., Ben Simon, G. J., Safrin, M., Ohman, D. E., Kessler, E. (2004). Pseudomonas aeruginosa LasA Protease in Treatment of Experimental Staphylococcal Keratitis. Antimicrob. Agents Chemother. 48: 1681-1687 [Abstract] [Full Text]  
  • Myhre, A. E., Stuestol, J. F., Dahle, M. K., Overland, G., Thiemermann, C., Foster, S. J., Lilleaasen, P., Aasen, A. O., Wang, J. E. (2004). Organ Injury and Cytokine Release Caused by Peptidoglycan Are Dependent on the Structural Integrity of the Glycan Chain. Infect. Immun. 72: 1311-1317 [Abstract] [Full Text]  
  • Wu, J. A., Kusuma, C., Mond, J. J., Kokai-Kun, J. F. (2003). Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces. Antimicrob. Agents Chemother. 47: 3407-3414 [Abstract] [Full Text]  
  • von Eiff, C., Kokai-Kun, J. F., Becker, K., Peters, G. (2003). In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood. Antimicrob. Agents Chemother. 47: 3613-3615 [Abstract] [Full Text]  
  • Kokai-Kun, J. F., Walsh, S. M., Chanturiya, T., Mond, J. J. (2003). Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model. Antimicrob. Agents Chemother. 47: 1589-1597 [Abstract] [Full Text]  
  • Moore, M. R., Perdreau-Remington, F., Chambers, H. F. (2003). Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of Endocarditis. Antimicrob. Agents Chemother. 47: 1262-1266 [Abstract] [Full Text]  
  • Walsh, S., Shah, A., Mond, J. (2003). Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol. Antimicrob. Agents Chemother. 47: 554-558 [Abstract] [Full Text]  
  • Kiri, N., Archer, G., Climo, M. W. (2002). Combinations of Lysostaphin with {beta}-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 46: 2017-2020 [Abstract] [Full Text]  
  • Boyle-Vavra, S., Carey, R. B., Daum, R. S. (2001). Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother 48: 617-625 [Abstract] [Full Text]  
  • Climo, M. W., Ehlert, K., Archer, G. L. (2001). Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 1431-1437 [Abstract] [Full Text]  
  • Nelson, D., Loomis, L., Fischetti, V. A. (2001). Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 10.1073/pnas.061038398v1 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Allen, G. P., Hershberger, E., Rybak, M. J. (2000). Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model. Antimicrob. Agents Chemother. 44: 2991-2998 [Abstract] [Full Text]  
  • Chesneau, O., Morvan, A., Solh, N. E. (2000). Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J Antimicrob Chemother 45: 887-890 [Abstract] [Full Text]  
  • Backo, M., Gaenger, E., Burkart, A., Chai, Y. L., Bayer, A. S. (1999). Treatment of Experimental Staphylococcal Endocarditis Due to a Strain with Reduced Susceptibility In Vitro to Vancomycin: Efficacy of Ampicillin-Sulbactam. Antimicrob. Agents Chemother. 43: 2565-2568 [Abstract] [Full Text]  
  • Nelson, D., Loomis, L., Fischetti, V. A. (2001). Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 98: 4107-4112 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»